Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

Direct Payment

$120,000.00

CD47-LLO: An antibody toxin conjugate for antigen presentation in cancer immunotherapy

EF 2025-26

Résumé
The immune system consists of two divisions: innate and adaptive immunity. Innate immune cells called phagocytes survey the body for foreign invaders and "eat" them in a process called phagocytosis. This process educates adaptive immune cells such as T cells to mount a targeted response. In cancer, tumors suppress the immune system's ability to fight back. To combat this, immune checkpoint inhibition is a therapy that reinvigorates a T cell's ability to kill cancer. While effective in some cancers, pancreatic cancer remains resistant, necessitating new therapeutic strategies. Engaging the innate immune system in combination with checkpoint blockade is one strategy to boost anti-tumor immunity. To do this, our proposed therapy called CD47-LLO programs innate immune cells to be anti-tumor. It does so by 1) enhancing phagocytosis by blocking CD47, a "don't eat me" signal on cancer cells and 2) a protein called listeriolysin-O triggers the production of signaling molecules called cytokines that help immune cells communicate and mount a coordinated response. Thus far we have shown that CD47-LLO is effective at improving survival outcomes in mouse models of pancreatic cancer and sensitizes these resistant tumors to respond to immune checkpoint inhibition. To understand the mechanisms that underly this sensitization, this proposal seeks to understand if CD47-LLO improves the immune system's ability to respond broadly to a wide range of immune triggers. In addition, we seek to validate our findings using translationally relevant mouse models implanted with patient samples. If successful, the combinatorial approach of investigating the molecular mechanisms and translational potential of CD47-LLO will support bench-to-bedside translation of a novel therapeutic with potential to destroy pancreatic cancer and uncover how antigen presentation drives anti-tumor immunity.
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Bénéficiaire
Emplacement
Texas, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
556147
Name
Wu Annette
Region
Texas
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
CD47-LLO: An antibody toxin conjugate for antigen presentation in cancer immunotherapy
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Antibody Drug Conjugate; Checkpoint Blockade; Flow Cytometry; Humanized Mouse Models; Immunotherapy; Multiplexed Immunofluorescence; Pancreatic Cancer; Single Cell Rna Sequencing
Abstract
The immune system consists of two divisions: innate and adaptive immunity. Innate immune cells called phagocytes survey the body for foreign invaders and "eat" them in a process called phagocytosis. This process educates adaptive immune cells such as T cells to mount a targeted response. In cancer, tumors suppress the immune system's ability to fight back. To combat this, immune checkpoint inhibition is a therapy that reinvigorates a T cell's ability to kill cancer. While effective in some cancers, pancreatic cancer remains resistant, necessitating new therapeutic strategies. Engaging the innate immune system in combination with checkpoint blockade is one strategy to boost anti-tumor immunity. To do this, our proposed therapy called CD47-LLO programs innate immune cells to be anti-tumor. It does so by 1) enhancing phagocytosis by blocking CD47, a "don't eat me" signal on cancer cells and 2) a protein called listeriolysin-O triggers the production of signaling molecules called cytokines that help immune cells communicate and mount a coordinated response. Thus far we have shown that CD47-LLO is effective at improving survival outcomes in mouse models of pancreatic cancer and sensitizes these resistant tumors to respond to immune checkpoint inhibition. To understand the mechanisms that underly this sensitization, this proposal seeks to understand if CD47-LLO improves the immune system's ability to respond broadly to a wide range of immune triggers. In addition, we seek to validate our findings using translationally relevant mouse models implanted with patient samples. If successful, the combinatorial approach of investigating the molecular mechanisms and translational potential of CD47-LLO will support bench-to-bedside translation of a novel therapeutic with potential to destroy pancreatic cancer and uncover how antigen presentation drives anti-tumor immunity.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Wu, Annette
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~